Skin health and disease最新文献

{"title":"Oral and topical vitamin D treatment strategies in psoriasis.","authors":"Michelle Mai, Ingrid Lazaridou, Fatima N Mirza, Karen H Costenbader, Abrar A Qureshi, Eunyoung Cho","doi":"10.1093/skinhd/vzaf010","DOIUrl":"10.1093/skinhd/vzaf010","url":null,"abstract":"<p><p>Psoriasis is a prevalent skin disorder affecting approximately 2-3% of the population in the USA. Its complex and varied presentations necessitate a diverse range of available therapeutic options. While topical corticosteroid therapy is conventionally employed as first-line treatment, long-term usage increases the risk of adverse events, prompting the consideration of alternatives including steroid-sparing agents such as vitamin D. In this article, we review literature from topical and oral vitamin D trials for the treatment of psoriasis. Topically, vitamin D analogues have been well established as an effective long-term treatment, particularly when used in combination with other therapies. Moreover, combination therapy with immunomodulators such as apremilast and methotrexate has shown promise as well. Conversely, oral vitamin D supplementation trials have yielded more inconsistent results, with some supplementation clinical trials showing significant psoriasis resolution and others showing no significant changes in psoriasis outcome. Vitamin D deficiency status, seasonal variation and body mass index were factors that may have modulated the therapeutic effect of vitamin D supplementation. Further study combining vitamin D supplementation with pre-existing treatments may also augment the effect of monotherapy. Studies on the synergistic effects of combination therapies with oral vitamin D or the development of foam-based or microneedle drug delivery systems may be promising next steps.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 3","pages":"178-190"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin cancer screening practices of UK hairdressers and barbers for their customers: a preliminary study.","authors":"Helen Fleming, Chris Wells, Andrew Williams, Rebecca Stores","doi":"10.1093/skinhd/vzaf015","DOIUrl":"10.1093/skinhd/vzaf015","url":null,"abstract":"<p><strong>Background: </strong>Head-and-neck skin cancers have a worse prognosis than those that develop elsewhere on the body. Self-screening this area for suspicious skin changes can be difficult. Hairdressers and barbers observe this area closely during hair appointments and could bring their customers' attention to suspicious skin changes earlier.</p><p><strong>Objectives: </strong>To investigate a sample of UK hairdressers' and barbers' skin cancer education, customer screening practices and influences on screening, and to compare hairdressers' and barbers' screening practices.</p><p><strong>Methods: </strong>Stratified random sampling was utilized to select hairdressers and barbers working in a UK city. Participants were invited to complete a survey.</p><p><strong>Results: </strong>Thirty-seven participants completed the survey. Five per cent reported having had skin cancer awareness training and 24% were screening customers. Thirty-five per cent had advised a customer of a suspicious mole or skin lesion; of these participants, 39% had had customers diagnosed with skin cancer. 'Not having received training' was reported by 65% of participants as a deterrent to screening. Knowing someone who had experienced skin cancer was significantly associated with screening and advising customers of suspicious skin changes. Most participants (92%) indicated they would like, or maybe like, skin cancer awareness training.</p><p><strong>Conclusions: </strong>In this UK city study, perceived knowledge of the signs and symptoms of skin cancer appeared to arise from knowing someone who had experienced skin cancer rather than formal training. Lack of skin cancer education was a deterrent to screening, but most participants would like training. Trained hairdressers and barbers could potentially provide regular head-and-neck skin screening for customers.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 3","pages":"203-209"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.","authors":"Elizaveta Gribaleva, Niels Steen Krogh, David Prieto-Merino, Bolaji Coker, Abaigeal Jackson, Ahmet Akkoc, Thomas Birkner, Erwin Bruninx, Con Hennessy, Kaitlyn Chan, Lara Cutlar, Byron Farrell, Godfrey Fletcher, Louise Gerbens, Anne Grete Frostrup, Dan Henrohn, Ariënna Hyseni, Alan D Irvine, Rayka Malek, Caitriona McCarthy, Ida Vittrup, Wouter Ouwerkerk, Rowena Randall, Phyllis I Spuls, Simon Francis Thomsen, Dmitri Wall, Stephan Weidinger, Thomas Werfel, Jochen Schmitt, Carsten Flohr","doi":"10.1093/skinhd/vzaf020","DOIUrl":"10.1093/skinhd/vzaf020","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a common chronic inflammatory skin condition. Currently, there is a lack of real-world evidence regarding the effectiveness of systemic therapies for moderate-to-severe AD. Abrocitinib is a novel Janus kinase 1 selective inhibitor licensed for AD in adults and adolescents requiring systemic treatment. The DREAM TO TREAT AD (D2T AD) study was set up to collect real-world data on abrocitinib and conventional systemic treatment use in moderate-to-severe AD. It aims to describe treatment patterns and effectiveness within a 3-year follow-up period in five registers: Ireland [Atopic Eczema Systemic Therapy Register (A-STAR) Ireland], Denmark (SCRATCH), Germany (TREATgermany), the Netherlands and Belgium (TREAT NL/BE), and the UK (A-STAR UK).</p><p><strong>Methods: </strong>The study protocol and methodology were developed collaboratively by academics of the participating registers with the study funder. The study follow-up timepoints and outcomes are based on an international Delphi exercise previously run by the TREAT Registry Taskforce. All five registers collect data in several domains, including patients' characteristics and treatment outcomes in patients receiving systemic treatment. Assignment to treatment was decided by the treating clinician. Data collected by the registers will be transformed into harmonized datasets and then to analytical datasets (ADS) to address research questions. Study objectives include describing patient baseline characteristics, in addition to clinician- (Eczema Area and Severity Index) and patient-reported outcomes [Patient-Reported Eczema Measure (POEM), Children's/Dermatology Life Quality Index (C/DLQI), Peak Pruritus Numeric Rate Scale (PP-NRS)] at baseline and follow-up, as well as treatment patterns while on abrocitinib and conventional systemic treatments. The ADS will be analysed using the novel DataSHIELD solution that enables centralized statistical analysis on decentralized data (i.e. without data leaving the register of origin). The DataSHIELD solution includes central analytic hubs (CAHs) and local data nodes (LDNs). CAH can remotely interrogate LDNs via an internet connection using analytical commands. Each LDN produces local statistical results that are sent back to the CAH, which can then combine the results from all LNDs without seeing any patient-level data.</p><p><strong>Discussion: </strong>D2T AD undertakes a novel federated data analysis approach across five registers in observational dermatology research and will provide crucial information on AD treatment outcomes for clinical decision-making, in addition to proving the feasibility of this type of scientific collaboration.</p><p><strong>Protocol registration: </strong>EMA RWD Catalogue (EU PAS no.: 108468; study ID: 199009; https://catalogues.ema.europa.eu/node/3894/administrative-details).</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 3","pages":"196-202"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trisomy 18 with widespread calcinosis cutis.","authors":"Airin Sato, Yu Matsui, Teruhiko Makino, Tadamichi Shimizu","doi":"10.1093/skinhd/vzaf023","DOIUrl":"10.1093/skinhd/vzaf023","url":null,"abstract":"<p><p>Trisomy 18 is the second most common autosomal trisomy, associated with high mortality, with only 5-10% of affected individuals surviving beyond the first year of life. Consequently, comorbidities in long-term survivors are rarely reported. We describe the case of a 6-year-old East Asian girl with trisomy 18 who presented with calcinosis cutis. The patient initially developed a firm, non-tender subcutaneous nodule on the left wrist, which later spread to the forearm and upper arm. Physical examination and imaging revealed extensive subcutaneous nodules in other extremities. High-frequency ultrasonography showed hypoechogenic masses with posterior acoustic shadows, while skin biopsy revealed fat necrosis and calcium deposition. No significant abnormalities were detected in the levels of calcium, phosphorus, parathyroid hormone or vitamin D. Based on laboratory findings and the patient's medical history, metabolic, nutritional, inflammatory and iatrogenic causes of calcinosis cutis were unlikely. Consequently, the condition was classified as either dystrophic or idiopathic calcinosis cutis. The patient was managed as an outpatient without specific treatment. This report discusses the mechanisms of calcinosis cutis and the reasons for the limited research on its association with trisomy 18. To our knowledge, this is the first report describing calcinosis cutis as a concomitant condition in a paediatric patient with trisomy 18, and it is anticipated that increased awareness of this disease may lead to a rise in reported cases in the future.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 3","pages":"227-230"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dyschromatosis universalis hereditaria with <i>SASH1</i> mutation improved with picosecond laser treatment.","authors":"Liyan Yuan, Ying Luo, Chao Yang, Mao-Qiang Man, Bin Yang, Zhenfeng Liu","doi":"10.1093/skinhd/vzaf024","DOIUrl":"10.1093/skinhd/vzaf024","url":null,"abstract":"<p><p>Dyschromatosis universalis hereditaria (DUH) is a rare autosomal dominant pigmentary skin disorder characterized by hypo- and hyperpigmented macules over the body. Although DUH is associated with mutations in <i>ABCB6</i> and <i>SASH1</i>, other factors also contribute to the pathogenesis of DUH, as the lesions typically appear on the exposed areas of the skin and do not develop in all individuals with <i>SASH1</i> mutations. Most reported cases of <i>SASH1</i> mutations are in Chinese or Japanese patients who do not require treatment. Herein, we report a rare case of an 11-year-old boy presenting with an 8-year history of widespread brown spots. The lesions, which began on his face and spread to the trunk, limbs and oral mucosa, developed without photosensitivity. Whole-exome sequencing helped identify a heterozygous <i>SASH1</i> mutation (c.1529G > A; exon13, NM_015278.5). Initial treatment with intense pulsed light did not result in any improvement; however, subsequent picosecond laser treatment led to significant improvement. Hence, this case highlights the phenotypic variability of DUH associated with <i>SASH1</i> mutations and the potential role played by additional genetic or environmental factors in disease expression. Furthermore, picosecond laser treatment may be effective against hyperpigmented lesions, although further studies are required to assess its long-term efficacy and safety.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 3","pages":"191-195"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?","authors":"Michaela Houghton, Annwyne Houldsworth","doi":"10.1093/skinhd/vzaf022","DOIUrl":"10.1093/skinhd/vzaf022","url":null,"abstract":"<p><p>Oncolytic viruses (OVs) can destroy cancer cells without harming healthy cells. This review explores the mechanisms by which OVs operate and the methods of delivering them. Melanoma is a common type of skin cancer with increasing prevalence in the UK; therefore, finding effective strategies to combat the disease is paramount. To understand the potential of OVs in treating melanoma, different types of viruses will be reviewed. Talimogene laherparepvec (T-VEC) is the only OV to be approved for treating melanoma; this review aims to understand the efficacy of T-VEC as a monotherapy and combined with other treatments. There is substantial evidence to support the use of OVs in treating melanoma by synthesizing the current perspectives of their use where they proved to be effective in clinical trials, as monotherapies and in combination with other treatments, as well as exciting innovative ventures using novel virus species. Gaps are also highlighted in the research, such as determining the influence that cancer gene mutational status has on how the tumour cells react to treatment, a concept that should also be considered in future research.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"102-113"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Best foot forward: podiatrists' insight and awareness of melanoma of the foot-a questionnaire study.","authors":"Brian Nolan, Cathal O'Connor, Michelle Murphy","doi":"10.1093/skinhd/vzaf008","DOIUrl":"10.1093/skinhd/vzaf008","url":null,"abstract":"<p><p>A significant proportion of melanomas arise on the lower limb, which may present to podiatrists. In this study, two-thirds (67.6%) of podiatrists reported reviewing pigmented lesions, and two-thirds (69.6%) reported identifying a lesion suspicious for melanoma. Only 57.8% of podiatrists felt comfortable contacting their patient's general practitioner, and most podiatrists (82.2%) felt they received inadequate training in melanoma.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 3","pages":"240-241"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-producing a randomized controlled trial on the frequency of bathing in eczema: description of a citizen science approach.","authors":"Arabella Baker, Natalie Bonsu, Laura Howells, Ingrid Muller, Eleanor J Mitchell, Fiona Cowdell, Firoza Davies, Mars Eddis-Finbow, Alan Montgomery, Devin Patel, Goldie Putrym, Matthew J Ridd, Miriam Santer, Amanda Roberts, Kim S Thomas","doi":"10.1093/skinhd/vzaf005","DOIUrl":"10.1093/skinhd/vzaf005","url":null,"abstract":"<p><strong>Background: </strong>Eczema is a prevalent, chronic, itchy skin condition that often persists into adulthood and significantly affects the quality of life of patients and their families. With no cure available at present, effective management is crucial. Although important patient priorities related to eczema self-management have been identified, they are rarely the focus of large, high-quality randomized controlled trials (RCTs).</p><p><strong>Objectives: </strong>To outline the methodology of using a citizen science approach to co-produce an online RCT on the frequency of bathing, to support the self-management of eczema.</p><p><strong>Methods: </strong>The co-production of the trial with patients living with eczema involved research prioritization, intervention development and trial design, all carried out through a series of online meetings and surveys.</p><p><strong>Results: </strong>Co-producing the trial took 9 months, consisting of 13 online meetings (5 to prioritize the topic, 4 to develop the intervention and 4 to design the trial), requiring 39 h of time commitment from members of the public (<i>n</i> = 12) with a total spending of £5440 on reimbursements. A prioritization survey (<i>n</i> = 120) identified the most popular research question as how often to bath/shower, receiving 49% of votes. Following an iterative refinement among the co-production group members, the trial research question was formulated. The intervention development survey (<i>n</i> = 169) established current bathing practices and interest in participating in the trial. Survey results informed the development of study materials and influenced decisions related to trial design. The finalized study materials included key information about the target behaviour (weekly bathing or daily bathing), frequently asked questions and common concerns. The trial design co-production group determined the eligibility criteria, defined the intervention and comparator, selected the outcome measures, determined the study duration and developed the recruitment strategy. The Eczema Bathing Study opened to recruitment on 29 January 2024 and over 50% of the target sample size of 390 have been recruited within the first 2 months.</p><p><strong>Conclusions: </strong>This paper provides a useful model for co-producing RCTs with members of the public. It describes the key stages of trial development (prioritization, intervention development, trial design) and contains information on the time and resources required to design trials using this approach.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"130-139"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marginal zone lymphoma masquerading as phymatous acne rosacea: a case study.","authors":"Hina S Baloch, Zhenghao Wang, Joy U L Staniforth, Azaharry Yaakub","doi":"10.1093/skinhd/vzaf026","DOIUrl":"10.1093/skinhd/vzaf026","url":null,"abstract":"<p><p>Marginal zone lymphoma (MZL) is an indolent B-cell lymphoma characterized by considerable heterogeneity in clinical presentation. Cutaneous MZL typically manifests as papules, plaques or nodules, often affecting the trunk and arms. Rare cases of MZL presenting as acne rosacea have been reported; however, these have been primarily reported as granulomatous rosacea. Specific evidence of MZL presenting as phymatous acne rosacea is extremely rare and not well documented in the medical literature. We report a rare case of primary systemic nodal MZL manifesting alongside cutaneous extra-nodal MZL, mimicking rhinophymatous and otophymatous acne rosacea. An 84-year-old White man with a 13-year history of nodal MZL, under active monitoring, presented with erythematous, swollen lesions on the ears and nose. This was initially diagnosed as acne rosacea; however, conventional treatment proved ineffective, and the patient was referred for dermatological evaluation. A skin biopsy from the earlobe revealed a diffuse infiltrate of small lymphoid B cells, positive for CD20, CD79a and BCL2, and negative for CD5 and CD23, consistent with cutaneous MZL. Further imaging revealed systemic involvement, with enlarged lymph nodes above and below the diaphragm and splenomegaly. The patient was started on R-CVP chemotherapy (rituximab, cyclophosphamide, vincristine and prednisolone), leading to significant improvement in both the skin lesions and systemic disease. However, due to chemotherapy intolerance, treatment was discontinued after four cycles. This case highlights a rare presentation of MZL, mimicking the features of phymatous acne rosacea, particularly rhinophyma and otophyma. The resemblance to rosacea, particularly phymatous subtypes, leads to initial misdiagnosis and delays in appropriate treatment. This underlines the importance of considering alternative diagnoses in patients with atypical or nonresponsive dermatological conditions, especially when conventional therapies fail. Early biopsy and histological evaluation are critical for ensuring timely diagnosis and treatment, potentially improving patient outcomes.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 3","pages":"231-235"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of refractory alopecia areata successfully treated by combining delgocitinib ointment with excimer laser.","authors":"Yukito Kakeji, Toshiaki Kogame, Yosuke Yagi, Naotomo Kambe, Kenji Kabashima","doi":"10.1093/skinhd/vzaf013","DOIUrl":"10.1093/skinhd/vzaf013","url":null,"abstract":"<p><p>Alopecia areata (AA) is an autoimmune disease that causes recurrent hair loss. No treatment has been effective in the long term because of the unstable efficacy and possible side effects. AA is primarily driven by Th1-type inflammation, centred around CD8⁺ T cells and interferon-γ (IFN-γ). Recent studies have revealed that the Janus kinase (JAK) family is also involved in the pathogenesis of AA, leading to JAK inhibitors emerging as a treatment for AA. We present a case of a 39-year-old Japanese woman with severe AA who exhibited a Severity of Alopecia Tool (SALT) score 80 accompanied by atopic dermatitis (AD). Despite conventional treatments, the condition worsened from a SALT score of 80 to 100. We subsequently attempted treatment with an excimer laser (EL), but no hair regrowth was observed. However, the introduction of 0.5% delgocitinib ointment in combination with EL led to complete hair regrowth beginning 2 months later, with complete remission achieved after 1 year. This case highlights the potential efficacy of combining delgocitinib ointment with EL in treating severe AA, particularly in patients with AD. The findings suggest that this combination therapy may provide a safer and more effective alternative to oral JAK inhibitors. Nevertheless, further studies are needed to elucidate the underlying mechanisms and fully evaluate the therapeutic synergy.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"154-157"},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}